• Explore /
  • Poster
  • / Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (UC) progressing on platinum-based chemotherapy and PD1/L1 inhibitors (ICB): Double antibody drug conjugate (DAD) phase I trial.

Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (UC) progressing on platinum-based chemotherapy and PD1/L1 inhibitors (ICB): Double antibody drug conjugate (DAD) phase I trial.

Abstract Poster

Authors

Bradley McGregor

Bradley Alexander McGregor

Dana-Farber Cancer Institute, Boston, MA

Bradley Alexander McGregor , Lucia Kwak , Charlene Mantia , Arvind Ravi , Jacob E Berchuck , Praful Ravi , Wenxin Xu , Martha Tuff , Joaquim Bellmunt , Xin Gao , Rajitha Sunkara , Guru P. Sonpavde

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04724018

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr TPS588)

DOI

10.1200/JCO.2022.40.6_suppl.TPS588

Abstract #

TPS588

Poster Bd #

M5

Abstract Disclosures

Similar Posters

First Author: Bradley Alexander McGregor

Poster

2024 ASCO Genitourinary Cancers Symposium

Mechanisms and strategies to overcome resistance to enfortumab vedotin in bladder cancer.

Mechanisms and strategies to overcome resistance to enfortumab vedotin in bladder cancer.

First Author: Kevin Chang

First Author: Scott T. Tagawa

First Author: Rohan Garje